Page last updated: 2024-08-17

spironolactone and metformin

spironolactone has been researched along with metformin in 56 studies

Research

Studies (56)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.79)	18.2507
2000's	11 (19.64)	29.6817
2010's	28 (50.00)	24.3611
2020's	16 (28.57)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Campillo, NE; Guerra, A; Páez, JA	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Barclay, SC; Gibson, J; Lamey, PJ; Miller, S	1
Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL	1
Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM	1
Kelestimur, F; Sahin, Y	1
Ammini, AC; Dwivedi, SN; Eunice, M; Ganie, MA; Gulati, M; Gupta, N; Khurana, ML	1
Al-Inany, H	2
Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF	1
Bhatia, V	1
Conway, GS; Koulouri, O	1
Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE	1
Artini, PG; Cela, V; Di Berardino, OM; Monteleone, P; Papini, F; Ruggiero, M; Simi, G	1
Brodell, LA; Mercurio, MG	1
Bergstrom, KG	1
Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B	1
Appelbaum, H; Bonny, AE; Connor, EL; Cromer, B; DiVasta, A; Gomez-Lobo, V; Harel, Z; Huppert, J; Sucato, G	1
Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG	1
Joulak, I; Kaplan, J; Muneyyirci-Delale, O; Nacharaju, VL; Von Gizycki, H; Yang, L	1
Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P	1
Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA	1
Buzney, C; Buzney, E; Reynolds, RV; Sheu, J	1
Carter, B; Fedorowicz, Z; Pandis, N; van Zuuren, EJ	1
Bonnell, A; Moreno, LE; Neher, JO; Safranek, S	1
Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K	1
Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L	1
Arora, A; Kulshreshtha, B; Pahuja, I; Pant, S; Sharma, N	1
de Zegher, F; Del Río, L; Díaz, M; Ibáñez, L; López-Bermejo, A; Pozo, ÓJ; Sebastiani, G	1
Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M	1
Damle, L; Gomez-Lobo, V; Sullivan, S; Uliassi, N	1
de Zegher, F; Garcia-Beltran, C; Ibáñez, L; López-Bermejo, A; Malpique, R; Sánchez-Infantes, D; Taxerås, SD	1
Kyrgidis, A; Nikolakis, G; Zouboulis, CC	1
de Zegher, F; Ibáñez, L	1
Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA	1
Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A	1
Liu, YT; Long, SL; Mo, ZC; Xie, YJ; Zeng, X	1
Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA	1
Cereijo, R; de Zegher, F; García-Beltran, C; Ibáñez, L; López-Bermejo, A; Malpique, R; Quesada-López, T; Villarroya, F	1
Alhifany, AA; Almalki, HH; Almohammed, OA; Alshibani, TM	1
Brotons, P; Carbonetto, B; de Zegher, F; Garcia-Beltran, C; González-Torres, P; Henares, D; Ibáñez, L; López-Bermejo, A; Malpique, R; Muñoz-Almagro, C	1
Cairó, M; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J	1
Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H	1
Asadipooya, K; Bakhtiari, M	1
Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE	1
Bassols, J; Carreras-Badosa, G; de Zegher, F; Garcia-Beltran, C; Ibáñez, L; López Bermejo, A	1
Hsiao, JL; Jeong, C; Masson, R; Shi, VY; Shih, T	1
Andersen, MS; Bas, F; Bassols, J; Darendeliler, F; de Zegher, F; Díaz, M; Dieris, B; Fanelli, F; Fröhlich-Reiterer, E; Gambineri, A; Garcia-Beltran, C; Glintborg, D; Ibáñez, L; López-Bermejo, A; Malpique, R; Mann, C; Marin, S; Obermayer-Pietsch, B; Ravn, P; Reinehr, T; Renzulli, M; Salvador, C; Singer, V; Torres, JV; Vanky, E; Yildiz, M; Ødegård, R	1
Hao, SL; Meng, XY; Zhang, CL	1

Reviews

18 review(s) available for spironolactone and metformin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Current drug targets. Immune, endocrine and metabolic disorders, 2002, Volume: 2, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone	2002
Medical treatment regimens of hirsutism. Reproductive biomedicine online, 2004, Volume: 8, Issue:5 Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Spironolactone	2004
Polycystic ovary syndrome. Clinical evidence, 2004, Issue:12 Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; Spironolactone	2004
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. Ugeskrift for laeger, 2005, Aug-22, Volume: 167, Issue:34 Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Thiazolidinediones	2005
Insulin resistance in polycystic ovarian disease. Southern medical journal, 2005, Volume: 98, Issue:9 Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Luteinizing Hormone; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones	2005
Polycystic ovary syndrome. Clinical evidence, 2005, Issue:14 Topics: Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; Humans; Metformin; Polycystic Ovary Syndrome; Spironolactone	2005
A systematic review of commonly used medical treatments for hirsutism in women. Clinical endocrinology, 2008, Volume: 68, Issue:5 Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination; Female; Finasteride; Flutamide; Hirsutism; Humans; Metformin; Spironolactone; Thiazolidinediones; Treatment Outcome	2008
Best methods for identification and treatment of PCOS. Minerva ginecologica, 2010, Volume: 62, Issue:1 Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Hirsutism; Humans; Hyperandrogenism; Infertility, Female; Insulin Resistance; Menstruation Disturbances; Metformin; Obesity; Ovarian Follicle; Ovary; Polycystic Ovary Syndrome; PPAR gamma; Reproductive Techniques, Assisted; Spironolactone; Ultrasonography	2010
Hirsutism: Diagnosis and management. Gender medicine, 2010, Volume: 7, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diagnosis, Differential; Eflornithine; Female; Finasteride; Hair Removal; Hirsutism; Humans; Hypoglycemic Agents; Laser Therapy; Metformin; Mineralocorticoid Receptor Antagonists; Neoplasms; Ornithine Decarboxylase Inhibitors; Polycystic Ovary Syndrome; Spironolactone	2010
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. Journal of the American Academy of Dermatology, 2014, Volume: 71, Issue:5 Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, Combined; Dermatology; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones	2014
Interventions for hirsutism (excluding laser and photoepilation therapy alone). The Cochrane database of systematic reviews, 2015, Apr-28, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Female; Cyproterone Acetate; Desogestrel; Drug Combinations; Eflornithine; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Quality of Life; Randomized Controlled Trials as Topic; Spironolactone	2015
Clinical Inquiry: What therapies alleviate symptoms of polycystic ovary syndrome? The Journal of family practice, 2015, Volume: 64, Issue:4 Topics: Body Mass Index; Contraceptives, Oral; Diuretics; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Life Style; Metformin; Polycystic Ovary Syndrome; Pregnancy; Spironolactone; Thiazolidinediones	2015
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. Systematic reviews, 2015, Sep-23, Volume: 4 Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; Female; Flutamide; Humans; Hypoglycemic Agents; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Research Design; Spironolactone; Systematic Reviews as Topic; Thiazolidinediones; Young Adult	2015
Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. American journal of clinical dermatology, 2019, Volume: 20, Issue:4 Topics: Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Therapy, Combination; Finasteride; Hidradenitis Suppurativa; Humans; Metformin; Randomized Controlled Trials as Topic; Skin; Spironolactone; Treatment Outcome	2019
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clinica chimica acta; international journal of clinical chemistry, 2020, Volume: 502 Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone	2020
Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review. Journal of drugs in dermatology : JDD, 2023, Aug-01, Volume: 22, Issue:8 Topics: Finasteride; Flutamide; Hidradenitis Suppurativa; Humans; Liraglutide; Metformin; Spironolactone	2023
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis. Medicine, 2023, Oct-13, Volume: 102, Issue:41 Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastatin; Spironolactone; Testosterone	2023

Trials

15 trial(s) available for spironolactone and metformin

Article	Year
Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:6 Topics: Adolescent; Adult; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome	2004
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of gynecology and obstetrics, 2010, Volume: 281, Issue:1 Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinogen Degradation Products; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Weight Loss; Young Adult	2010
Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:5 Topics: Adolescent; Adult; Aldosterone; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Magnesium Oxide; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Young Adult	2013
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:2 Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Spironolactone; Testosterone; Young Adult	2014
Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:9 Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Composition; Body Mass Index; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Testosterone; Treatment Outcome; Waist-Hip Ratio	2013
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:1 Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Metrorrhagia; Mineralocorticoid Receptor Antagonists; Oligomenorrhea; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin; Spironolactone; Testosterone; Treatment Outcome; Young Adult	2016
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2017, Volume: 61, Issue:4 Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Intra-Abdominal Fat; Levonorgestrel; Metformin; Oligomenorrhea; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones	2017
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. European journal of endocrinology, 2017, Volume: 177, Issue:5 Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Spironolactone; Testosterone; Treatment Outcome; Young Adult	2017
Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials. Pediatric obesity, 2019, Volume: 14, Issue:5 Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; S100 Calcium-Binding Protein A4; Spironolactone	2019
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2020, Volume: 36, Issue:4 Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; India; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Spironolactone; Treatment Outcome; Young Adult	2020
Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments. The Journal of clinical endocrinology and metabolism, 2020, 03-01, Volume: 105, Issue:3 Topics: Adolescent; Biomarkers; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Pilot Projects; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome	2020
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2020, Volume: 52, Issue:2 Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Testosterone; Vitamin D; Young Adult	2020
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization. BMJ open diabetes research & care, 2020, Volume: 8, Issue:1 Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemokines, CXC; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Ethinyl Estradiol; Female; Gene Expression; Genetic Diseases, X-Linked; Gigantism; Heart Defects, Congenital; Humans; Hypoglycemic Agents; Insulin Resistance; Intellectual Disability; Levonorgestrel; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome	2020
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Scientific reports, 2021, 03-29, Volume: 11, Issue:1 Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Male; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Young Adult	2021
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a mult Trials, 2023, Sep-15, Volume: 24, Issue:1 Topics: Adolescent; Carotid Intima-Media Thickness; Clinical Trials, Phase II as Topic; Female; Humans; Insulin; Life Style; Metformin; Multicenter Studies as Topic; Pioglitazone; Polycystic Ovary Syndrome; Quality of Life; Randomized Controlled Trials as Topic; Spironolactone; Young Adult	2023

Other Studies

23 other study(ies) available for spironolactone and metformin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Neural computational prediction of oral drug absorption based on CODES 2D descriptors. European journal of medicinal chemistry, 2010, Volume: 45, Issue:3 Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3 Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs	2013
Grinspan's syndrome: a drug-induced phenomenon? Oral surgery, oral medicine, and oral pathology, 1990, Volume: 70, Issue:2 Topics: Aged; Aged, 80 and over; Atenolol; Bendroflumethiazide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Female; Furosemide; Glipizide; Humans; Hypertension; Lichen Planus; Metformin; Middle Aged; Mouth Diseases; Spironolactone; Syndrome	1990
The treatment of polycystic ovary syndrome. Minerva ginecologica, 2004, Volume: 56, Issue:1 Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss	2004
Everything old is new again: spironolactone and metformin in the treatment of acne. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:5 Topics: Acne Vulgaris; Clinical Trials as Topic; Dermatologic Agents; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome	2010
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:10 Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Medical Records; Metformin; Overweight; Polycystic Ovary Syndrome; Retrospective Studies; Spironolactone; Testosterone; Weight Loss; Young Adult	2012
Clinical variability in approaches to polycystic ovary syndrome. Journal of pediatric and adolescent gynecology, 2012, Volume: 25, Issue:4 Topics: Adolescent; Contraceptives, Oral; Cross-Sectional Studies; Data Collection; Exercise; Feeding Behavior; Female; Hormones; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Practice Patterns, Physicians'; Referral and Consultation; Sex Hormone-Binding Globulin; Spironolactone	2012
Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:4 Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Databases, Factual; Drug Prescriptions; Female; Glucose Intolerance; Guideline Adherence; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Practice Patterns, Physicians'; Spironolactone; United States	2013
Menstrual cyclicity post OC withdrawal in PCOS: Use of non-hormonal options. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2016, Volume: 36, Issue:6 Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Menstrual Cycle; Menstruation Disturbances; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Retrospective Studies; Spironolactone; Withholding Treatment; Young Adult	2016
Trends, in Diagnosis and Treatment of Polycystic Ovarian Syndrome by Specialty. The Journal of reproductive medicine, 2016, Volume: 61, Issue:9-10 Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Diagnostic Tests, Routine; Diuretics; Endocrinologists; Female; General Practitioners; Gynecology; Humans; Hydrocortisone; Hypoglycemic Agents; Life Style; Lipids; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Practice Patterns, Physicians'; Retrospective Studies; Spironolactone; Young Adult	2016
Polycystic ovary syndrome in adolescent girls. Pediatric obesity, 2020, Volume: 15, Issue:2 Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone	2020
Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials. BMC women's health, 2020, 04-05, Volume: 20, Issue:1 Topics: Contraceptives, Oral, Combined; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Spironolactone; Testosterone	2020
Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments. Pediatric obesity, 2021, Volume: 16, Issue:4 Topics: Adolescent; Female; Gastrointestinal Microbiome; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone	2021
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2021, Volume: 29, Issue:2 Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; Humans; Letrozole; Metformin; Phosphatidylinositol 3-Kinases; Pioglitazone; Polycystic Ovary Syndrome; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-akt; Signal Transduction; Spironolactone	2021
Metainflammation in COVID-19. Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Obesity; Orlistat; Peptidyl-Dipeptidase A; SARS-CoV-2; Spironolactone; Thiazolidinediones	2022
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care. Drug safety, 2022, Volume: 45, Issue:11 Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid	2022
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions. Hormone research in paediatrics, 2023, Volume: 96, Issue:5 Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Spironolactone; Thyrotropin	2023